Kosj Yamoah1, Amy Walker2, Elaine Spangler2, Charnita M Zeigler-Johnson3, Bruce Malkowicz2, David I Lee2, Adam P Dicker3, Timothy R Rebbeck2, Priti Lal2. 1. Department of Radiation Oncology, Kimmel Cancer Center and Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, PA. Electronic address: jkosjc@gmail.com. 2. The Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 3. Department of Radiation Oncology, Kimmel Cancer Center and Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, PA.
Abstract
INTRODUCTION: The purpose of the study was to determine whether racial differences exist in the pattern of local disease progression among men treated with radical prostatectomy (RP) for localized prostate cancer (PCa), which is currently unknown. In this study we evaluated the pattern of adverse pathologic features in an identical cohort of African-American (AA) and Caucasian (CS) men with PCa. PATIENTS AND METHODS: The overall cohort consisted of 1104 men (224 AA, and 880 CS) who underwent RP between 1990 and 2012. We compared preoperative factors and pathologic outcomes after RP across race groups. Multivariate analysis was used to identify factors predictive of adverse pathologic outcomes. The effect of race on adverse pathologic outcomes and biochemical control rate (BCR) was evaluated using multivariate regression model and Kaplan-Meier analysis. RESULTS: The 10-year BCR was 59% versus 82% in AA and CS men, respectively (P = .003). There was no significant difference in extraprostatic spread (P = .14), positive surgical margin (P = .81), lymph node involvement (P = .71), or adverse pathologic features (P = .16) across race groups. However, among patients with ≥ 1 adverse pathologic features, AA men had higher rate of seminal vesicle invasion (SVI) compared with CS men (51% vs. 30%; P = .01). After adjusting for known predictors of adverse pathologic features AA race remained a predictor of SVI. CONCLUSION: AA men have an increased risk of SVI after RP, particularly among men with Gleason ≤ 6 disease. This might represent racial differences in the biology of PCa disease progression, which contribute to poorer outcomes in AA men.
INTRODUCTION: The purpose of the study was to determine whether racial differences exist in the pattern of local disease progression among men treated with radical prostatectomy (RP) for localized prostate cancer (PCa), which is currently unknown. In this study we evaluated the pattern of adverse pathologic features in an identical cohort of African-American (AA) and Caucasian (CS) men with PCa. PATIENTS AND METHODS: The overall cohort consisted of 1104 men (224 AA, and 880 CS) who underwent RP between 1990 and 2012. We compared preoperative factors and pathologic outcomes after RP across race groups. Multivariate analysis was used to identify factors predictive of adverse pathologic outcomes. The effect of race on adverse pathologic outcomes and biochemical control rate (BCR) was evaluated using multivariate regression model and Kaplan-Meier analysis. RESULTS: The 10-year BCR was 59% versus 82% in AA and CS men, respectively (P = .003). There was no significant difference in extraprostatic spread (P = .14), positive surgical margin (P = .81), lymph node involvement (P = .71), or adverse pathologic features (P = .16) across race groups. However, among patients with ≥ 1 adverse pathologic features, AA men had higher rate of seminal vesicle invasion (SVI) compared with CS men (51% vs. 30%; P = .01). After adjusting for known predictors of adverse pathologic features AA race remained a predictor of SVI. CONCLUSION: AA men have an increased risk of SVI after RP, particularly among men with Gleason ≤ 6 disease. This might represent racial differences in the biology of PCa disease progression, which contribute to poorer outcomes in AA men.
Authors: M Roach; J Krall; J W Keller; C A Perez; W T Sause; R L Doggett; M Rotman; H Russ; M V Pilepich; S O Asbell Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038
Authors: Badar M Mian; Patricia Troncoso; Koji Okihara; Viju Bhadkamkar; Dennis Johnston; Adriana O Reyes; R Joseph Babaian Journal: J Urol Date: 2002-04 Impact factor: 7.450
Authors: Cyrille Bastide; Dominique Rossi; Eric Lechevallier; Franck Bladou; David Barriol; Denis Bretheau; Vincent Grisoni; Julien Mancini; Sophie Giusiano; Christophe Eghazarian; Antoine Van Hove Journal: BJU Int Date: 2011-08-18 Impact factor: 5.588
Authors: Hideshige Koh; Michael W Kattan; Peter T Scardino; Kazuho Suyama; Norio Maru; Kevin Slawin; Thomas M Wheeler; Makoto Ohori Journal: J Urol Date: 2003-10 Impact factor: 7.450
Authors: Debasish Sundi; Ashley E Ross; Elizabeth B Humphreys; Misop Han; Alan W Partin; H Ballentine Carter; Edward M Schaeffer Journal: J Clin Oncol Date: 2013-06-17 Impact factor: 44.544
Authors: Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544
Authors: Roble G Bedolla; Dimpy P Shah; Shih-Bo Huang; Robert L Reddick; Rita Ghosh; Addanki P Kumar Journal: Mol Carcinog Date: 2019-03-11 Impact factor: 4.784
Authors: Elio Mazzone; Marco Bandini; Felix Preisser; Sebastiano Nazzani; Zhe Tian; Firas Abdollah; Denis Soulieres; Markus Graefen; Francesco Montorsi; Shahrokh Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: Can Urol Assoc J Date: 2019-06 Impact factor: 1.862
Authors: Shivanshu Awasthi; Travis Gerke; Vonetta L Williams; Francis Asamoah; Angelina K Fink; Rajesh Balkrishnan; Jong Y Park; Kosj Yamoah Journal: Cancer Control Date: 2019 Jan-Dec Impact factor: 3.302
Authors: Vonetta L Williams; Shivanshu Awasthi; Angelina K Fink; Julio M Pow-Sang; Jong Y Park; Travis Gerke; Kosj Yamoah Journal: Cancer Med Date: 2018-03-30 Impact factor: 4.452